TL-895 是口服有效的，ATP 竞争性的，以及高度选择性和不可逆的BTK抑制剂，IC50和Ki分别为 1.5 nM 和 11.9 nM。TL-895在 JAKi 复发/难治性骨髓纤维化、急性髓系白血病、COVID-19 和癌症方面有研究的价值。

TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.

1415823-49-2

DMSO:250 mg/mL (558.66 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years